Antibody–Drug Conjugates: Advancing from Magic Bullet to Biological Missile

Abstract

Precision drug development is focusing on targeting tumor cell surface proteins for therapeutic delivery, maximizing bio-marker identified on-target damage to the tumor while minimizing toxicity. A recent article demonstrated high expression of B7-H4 antigen on resistant ovarian cancer cells and described preclinical activity of B7-H4–directed antibody–drug conjugate.